PT - JOURNAL ARTICLE AU - Mujdat Zeybel AU - Muhammad Arif AU - Xiangyu Li AU - Ozlem Altay AU - Mengnan Shi AU - Murat Akyildiz AU - Burcin Saglam AU - Mehmet Gokhan Gonenli AU - Buket Yigit AU - Burge Ulukan AU - Dilek Ural AU - Saeed Shoaie AU - Hasan Turkez AU - Jens Nielsen AU - Cheng Zhang AU - Mathias Uhlén AU - Jan Borén AU - Adil Mardinoglu TI - Multi-omics analysis reveals the impact of microbiota on host metabolism in hepatic steatosis AID - 10.1101/2021.05.22.21257482 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.22.21257482 4099 - http://medrxiv.org/content/early/2021/05/23/2021.05.22.21257482.short 4100 - http://medrxiv.org/content/early/2021/05/23/2021.05.22.21257482.full AB - Non-alcoholic fatty liver disease (NAFLD) is a complex disease involving alterations in multiple biological processes regulated by the interactions between obesity, genetic background and environmental factors including the microbiome. To decipher hepatic steatosis (HS) pathogenesis by excluding critical confounding factors including genetic variants, obesity and diabetes, we characterized 56 heterogeneous NAFLD patients by generating multi-omics data including oral and gut metagenomics as well as plasma metabolomics and inflammatory proteomics data. We explored the dysbiosis in the oral and gut microbiome and revealed host-microbiome interactions based on global metabolic and inflammatory processes. We integrated this multi-omics data using the biological network and identified HS’s key features using multi-omics data. We finally predicted HS using these key features and validated our findings in a validation dataset, where we characterized 22 subjects with varying degree of HS.Significance statement The oral and gut microbiota alterations have been linked to NAFLD. There is a lack of data on multi-omics characteristics of hepatic steatosis by exclusion of major confounding factors of obesity and metabolic syndrome. We observed that the oral and gut microbiota remodelling starts at early stages of the NAFLD spectrum, independent of obesity and metabolic syndrome. Our analysis suggested that the bacterial diversity is correlated with multi-omics signatures in NAFLD and our predictive model created based on multi-omics variables can successfully predict hepatic steatosis. The components of the multi-omics signatures may serve as biomarkers and can be pharmaceutically targeted. Future clinical trials with microbiota manipulation could consider intervention at early stages of NAFLD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financially supported by ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Koc University ethics committee approved the study (Decision No: 2018.351.IRB1.043, Decision Date: 15 May 2019).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with this study are available in the main text or the supplementary materials.